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Abstract

ASSESSMENT OF PERIPHERAL BDNF LEVELS OVER 30 DAYS

Sally Hang

Brain health, and the benefits of exercise have been linked to the biological
signaling molecule called brain-derived neurotrophic factor (BDNF). Animal and human
studies have provided some support for physical exercise as a mechanism for increasing
BDNF levels. However, results have been inconsistent, which may be attributed in part to
incomplete information about normal variation in circulating peripheral BDNF levels.
This investigation examined capillary-drawn whole blood samples from nine healthy
adult participants over 30 days with the goal of documenting variability in resting BDNF
levels and changes that may be attributed to physical exercise. It was hypothesized that
BDNF concentrations would stay relatively consistent (overall coefficient of variance not
exceeding 15%) and that physical exercise within 12 hours of blood sampling would
increase BDNF levels. In contrast to these expectations, the current study showed high
within-subject variability in resting BDNF levels across 30 days, and no association
between recent physical exercise and BDNF levels. However, having a variability
quantification is equally important for future methodology designs. While it remains
unclear if there are valid cognitive benefits link to BDNF, understanding human BDNF
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variability can be of general utility as a benchmark for designing and interpreting future
BDNF-related studies.
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1
Introduction

Neurotrophic factors are critical in brain development but also continue to
function in the mature nervous system to promote growth of new neurons (adult
neurogenesis; Gage, 2000) and maintain neuronal health and plasticity (as reviewed in
Binder & Scharfman, 2004). There are likely to be multiple biological mechanisms in the
periphery and the brain that mediate these beneficial effects, but one of the most
researched protein associated with brain health and aging is brain derived neurotropic
factor (BDNF). Many lines of evidence link BDNF concentration levels to brain and
cognitive health. Aging and neurological disease are both associated with reductions of
BDNF, while physical exercise and other methods have been used to increase BDNF
levels and provide some protection against those stresses (Oliff, Berchtold, Isackson, &
Cotman, 1998).
Disruptions in BDNF signaling have been linked to deadly effects on neurons,
including cell deterioration, impaired cellular metabolism and apoptosis (Miller &
Kaplan, 1998). Genetic variations such as the BDNF polymorphism gene referred to as
the Val66Met results in lower BDNF concentration levels and is associated with smaller
brain size and decreased activity-induced neurogenesis (Herting, Keenan, & Nagel,
2016). A study done by Hopkins, Davis, Vantieghem, Whalen, and Brucci (2012) showed
that having the homozygous polymorphism can impede the benefits of acute exercise
sessions. The studies cited above, and many other published studies, indicate the
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importance of BDNF proteins for maintaining brain and behavioral health and suggest
that physical exercise may promote health through a BDNF-dependent mechanism.
The effects of BDNF homeostasis on brain and behavior have also been studied
broadly in humans but with more variable results, which is not surprising considering the
many sources of uncontrolled variability in human subject samples. A major obstacle to
researching BDNF in humans is that there is no way to precisely measure BDNF levels in
brain tissue noninvasively. Most human studies measure peripheral BDNF levels using
saliva, serum, plasma, platelets and whole blood (as reviewed in Fernandes et al., 2015;
Ferris, Williams, & Shen, 2007; Hötting, Schickert, Kaiser, Röder, & Schmidt-Kassow,
2016; Kim et al., 2005; Klein at al., 2011; Komulainen et al., 2008; Lommatzsch et al.,
2005). Research supports peripheral blood BDNF appears to be a good indicator of brain
BDNF levels (Mandel, Ozdener, & Utermohlen, 2009; Marais, Stein, & Willie, 2009). In
psychopharmacology, there is an understanding that suggests that if it is present in the
platelets, then it’s almost certainly concurring in the brain, too. Studies by Thompson,
Weickert, Wyatt, and Webster (2011) found evidence of similar BDNF concentration
levels in brain and periphery of depressed patients. Further evidence suggests peripheral
BDNF modulates subpopulations of neuronal function (Lommatzsch, Bruan, & Renz,
2003). These studies suggest that we could use the peripheral as a “window to the brain”
to study BDNF concentration levels.
However, there is still inconsistency when assessing BDNF levels through
peripheral blood. Average BDNF found in serum levels are 100-fold higher when
compared to plasma levels. A possible explanation is that platelet degranulation occurs
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the clotting process (Fujimura et al., 2002). Other studies such as one done by Fujimura
et al. found evidence that suggests BDNF levels in serum is proportional to BDNF levels
in lysed platelets. This may be because a primary source of peripheral BDNF comes from
platelets (Karege, Bondolfi, Gervasoni, Schwald, Aubry, & Bertschy, 2005), studies
support BDNF levels in whole blood and plasma correlate with BDNF levels in
hippocampus; therefore, this shows the potential of peripheral measures of BDNF as a
biomarker tool (Klein et. al., 2011).
Several animal BDNF studies with different types of peripheral blood do
corroborate higher BDNF levels post recent physical exercise (Avdoshina et al., 2013;
Koo et al., 2013; Lee et al., 2009), but few speak of normal resting BDNF concentration
levels. In human participants, it is recommended to study BDNF through serum or whole
blood as plasma BDNF requires a more stringent sample handling (Elfving, Ploughmann,
& Wegener, 2010). This study aimed to evaluate the variability of BDNF levels under
normal life conditions over 30 days through capillary blood. This longer study design
generated new information about the variability of BDNF concentrations, which is a
longer span of time than has been measured previously, and also shed some light on how
reliable capillary-whole blood BDNF measurements are.

4
Literature Review

BDNF is one of the most abundant neurotrophic proteins produced in the
mammalian and animal central nervous system (CNS) that is highly implicated in the
neural plasticity, maintaining cell structure and promoting new neuronal cell growth.
They are found largely in the hippocampus followed by the cerebrum and other brain
areas. Like other neurotrophins, BDNF is firstly synthesized as a precursor, proBDNF,
which splits to generate the mature BDNF. Reichardt (2006) provided an overview for
the two ways BDNF exerts its effects: the tyrosine kinase receptor (TrKB) and panneurotrophin receptor p75 (p75NTR). The role of Trk receptors regulate axonal strength
and integrity as well as plasticity. TrK activation has different outcomes with
downstream cascades of ion channel activations, cell signaling, and mechanism specific
signaling with p75NTR being one of them (Huang & Reichardt, 2003).
The discovery of the TrK receptors led to an upsurge of neurotrophic research and
its various signaling pathways (Huang et al., 2003). While it is still being debated if
BDNF crosses the blood brain barrier (BBB) and circulates in the peripheral nervous
system (PNS), a study done by Pan, Banks, Fasold, Bluth, and Kastin (1999) concluded
that the peripheral BDNF in adult mice crosses the BBB via an efficient and saturable
transport system. Additionally, there is evidence of peripherally secreted BDNF from
non-neuronal peripheral cells, vascular smooth muscle cells, endothelial cells,
lymphocytes, and monocytes (Donovan et al, 1995). Whether BDNF crosses the BBB or
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is secreted peripherally, it supports that BDNF levels in the PNS correlates with the
BDNF levels in the CNS and brain diseases.
Maintaining BDNF homeostasis is imperative to maximal cell functioning. For
example, an imbalance in BDNF signaling can lead to abnormal cell development
patterns during critical visual cortex development and dendritic morphology (McAllister
et al., 1999). Low levels of BDNF signaling in non-dementia ageing women have been
correlated to cognitive impairments (Komulainen et al., 2008). Such correlations were
also seen in lower BDNF levels in depressed women when compared to depressed men
(Karege et al., 2002), Alzheimer’s disease, (Yasutake, Kuroda, Yanagawa, Okamura, &
Yoneda, 2006), and multiple sclerosis (Castellano, Patel, & White, 2008). Low BDNF
levels have also correlated with bipolar disorders on the mania spectrum but are much
lower during episodes on the depression spectrum (as reviewed in Fernandes et al., 2015).
These studies support the importance of maintaining BDNF homeostasis, but
unfortunately, direct connections between BDNF and cognitive function still need more
research.
There are external factors that could also influence BDNF signaling such as
environmental, seasonal changes and the amount of sunlight. A longitudinal, betweensubjects study assessed serum BDNF levels of Netherland residents from August 2004 to
March 2007. They found that on average, serum BDNF levels were lower from winter to
spring and highest from summer to winter (Molendijk et al., 2012). BDNF levels were
highest during the season with the most sunlight in summer and were lowest in winter
when there was the least amount of sunlight; sunlight within any given week varied from
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2 hours to 131 hours per week. They did a Post-hoc correlation of BDNF levels and
found lower levels associated with higher body mass index (BMI) with the higher BMIs
during the winter months (Molendijk et al., 2012). A possible explanation may be that
since there is less sunlight during the winter, that may be associated with less physical
exercise due to more time spent indoors due to winter conditions.
Daily circadian routines may have an impact on BDNF levels. Diurnal BDNF
secretion patterns have been linked to circadian rhythm of cortisol and hormones. In a
study with 34 healthy, young male participants, there were higher BDNF and cortisol
levels correlated with the morning samples and the BDNF concentrations decrease
throughout the day, showing lowest trends at night (Begliuomini et al., 2008) but other
studies showed BDNF level differences between genders with higher BDNF levels in
females (Choi, Bhang, & Ahn, 2011). In respect to hormones, oral contraception can pose
as a mediator of BDNF signaling. A study conducted to assess how a woman’s menstrual
cycle can affect BDNF signaling found that BDNF levels were highest during the
follicular phase and had a significant increase in BDNF during the luteal phase (Pluchino
et al., 2009). However, further research is necessary to address hormones related to
BDNF fluctuations.

BDNF and Physical Exercise
A growing body of literature is investigating mechanisms, such as physical
exercise, in order to maintain a wholesome and healthy lifestyle. Physical exercise is
essential for survival and has been engrained by evolution into many aspects of animal
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and mammalian biology. On a popular account, humans for example, were “born to run”
(Mattson, 2012). However, there is no consensus on the effect of physical exercise
intensity and duration i.e., differences between acute and regular physical exercise and its
effects on BDNF levels. Because of this, we still rely heavily on animal models to
explain this relationship (Cotman & Berchtold, 2002; van Praag, Shubert, Zhao, & Gage,
2005). For example, running has been shown to immediately impact rodent neurogenesis
and this trend is consistent with regular running-type activities (Kerr & Swain, 2011).
Regular exercise can increase baseline BDNF levels within the hippocampus, striatum,
and other cortical regions in laboratory animals (Ding et al., 2004; Neeper, GómezPinilla, Choi, & Cotman, 1996; Rasmussen et al., 2009). This speaks to the biological
need of maintaining a physically active lifestyle which may indirectly benefit other
factors such as mental or physiological health.
Physical exercise duration. Literature has increasingly supported the positive
effects of physical exercise on physical and mental health and longevity (Campos et al.,
2016). However, activity induced-BDNF signaling has been shown to be dependent on
duration of exercise and intensity (Ferris et al., 2007). Low intensity and shorter durations
may not significantly increase BDNF levels and extremely intense or long periods of
exercising can cause detrimental effects. Aerobic, resistance, endurance and high
intensity interval training (HiiT) all affect BDNF concentration levels in different ways.
Most studies report seeing effects after 30-minutes (reviewed in Roig, Norbrandt,
Geertseen, & Nielsen, 2013; Ferris, et al., 2007). Single sessions of acute 30-minute
exercises (short-term) of cycling at 60% VO2 max increased serum BDNF concentrations
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in healthy participants and multiple sclerosis patients (Gold et al., 2003). Long-term,
regular exercise has positive effects as well. Regular exercise facilitates long term
potentiation (LTP) which is repeated strengthening of synapses from its repeated usage
(van Praag, Christie, Sejnowski, & Gage 1999). Other benefits include physiological
changes such as hippocampal volume increases. For example, after one year of physical
exercise, hippocampal volume increased by 2% in aerobic exercising group when
compared to the stretching control group (Erickson et al., 2011). Typically, hippocampal
volume decreases by 1-2 % per year. This increase can equate to 1-2 years’ worth of
hippocampal volume. Therefore, we speculate that acute bouts of exercise could be
involved in jumpstarting or keeping this process going. Hopkins et al. (2012)
demonstrated that even short bouts of exercise can result in increased cognitive benefits
for individuals who are regular exercisers i.e., the cognitive benefits are dependent on
physical exercise history. This suggests the need for some type of physical exercise
routine.
Voluntary versus forced physical exercise. Self-selected routines have been
shown to be more beneficial in increasing BDNF signaling. Rodent models show that
voluntary, aerobic exercise (running wheel) increases hippocampal activity, growth and
BDNF circulation when compared to other forms of exercise and the control (Cotman &
Berchtold, 2002). But, having genetic predispositions or gene polymorphisms can also
influence BDNF signaling, brain structure and morphology even with participation in
physical exercise regimens. The BDNF gene polymorphism, Val66met, (Martinez-Levy
& Cruz-Fuentes, 2014) and the high affinity BDNF receptor, TrkB, are a correlate with
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deviations in synaptic physiology and disease risk (Avdoshina et al., 2013). This provides
evidence for BDNF signaling in brain homeostasis.
Other mediators include selective-phenotypic breeding. Nokia et al. (2016)
conducted a study using a contrasting rat model system. Adult male rats were selectively
bred up to the 17th generation to either have an innate high response trainer (HRT) or low
response trainer (LRT) to aerobic exercise. They were subjected to various exercise
activities: voluntary running wheel, forced endurance, forced resistance and a sedentary
group. The rats who were bred to have a HRT showed a greater adaptive ability to run
farther distances, carry more weight, and exhibited higher BDNF levels when compared
to controls and other forms of physical exercise. They also had more doublecortinpositive cell growth and more adult hippocampal neurogenesis (AHN). What’s more
intriguing is that the HRT rats in the voluntary running wheel group displayed the
maximum running speed increase, increase in doublecortin-positive cells, and most
increase in AHN (Nokia et al., 2016). Conversely, in another study rats who were
subjected to low-intensity, forced aerobic exercise had increased BDNF expression while
moderate-intensity, forced aerobic exercise suppressed it (Soya et al., 2007). Further
investigation is needed to support how genetic predispositions and physical exercise
routines can affect BDNF concentration levels.
Some additional factors to consider are inadequate training or overtraining, which
can show negative effects to the health, too. Inactivity has been related to increase health
mortality rates. While physical exercise has been linked to higher BDNF concentration
levels and better memory, short durations of 20 minutes or less did not show any effect
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on cognitive performance (Brisswalter, Collardeau, & Rene, 2002; Lambourne &
Tomporowski, 2010). In particular, when assessing memory, it is recommended that
physical exercise is performed at low intensities for 20 minutes or longer (reviewed in
Roig et al., 2013). However, it is important to consider that after 60 minutes of exercise
may cause exhaustion and dehydration (Tomporowski, 2003).
Intensity preference-based approaches. Preference-based approaches have been
gaining attention due to its beneficial practices. As seen in rodents, voluntary, self-paced
exercises with minimal outside stress induces positive results (Nokia et al., 2016). Selfselected exercise intensities increase the runner’s willingness to adhere to an exercise
program (Ekkekakis, 2009; Parfitt, Blisset, Rose, & Eston, 2009). Low to moderate
intensity programs also can increase working memory (Martins, Kavussanu, Willoughby,
& Ring, 2012). This may be attributed to how stress or continually elevated cortisol
levels can hinder one’s physical activity performance (Keinan, Friedland, Kahneman, &
Roth, 1999). Increases in stress and cortisol release could in turn lead to more erroneous
or unwanted responses. In a study with active females who were subjected to exercise
with the intention to keep the exercise intensity to feel “fairly good” or “good”, the “fairly
good” group did significantly better in the “good” group.; this supports the notion of
using affect to integrate into exercise regimens (Keinan et al., 1999; Williams et al,
2016). When conducted with sedentary participants’ willingness to participant in exercise
6 to 12 months, participants were more likely to do so after having a positive affect to a
small bout (30-minutes) of moderate-intensity exercise (Williams et al., 2008). This
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provides evidence in the willingness to apply physical activity research in sensible,
preference-based exercise routines.

BDNF, Genetics and Mental Health
Lower BDNF concentration levels have been correlated in neurodegenerative
disorders and diseases. It has been supported that lower BDNF mRNA expression has
been linked to depression (Altar, 1999). A meta-analysis found a significant association
between the BDNF Val66Met polymorphism and panic disorder (as reviewed in Chen, et
al., 2015). Although there are limitations in the research, this supports that having this
polymorphism gene poses the predisposition to panic disorder. Other studies have
investigated the neurotrophic hypothesis of depression (Dunman & Monteggia, 2006) and
found consistent evidence that having decreased levels of BDNF can lead to neuronal
atrophy and the use of antidepressants may help to reverse this. However, typical shortterm antidepressant treatment doesn’t increase BDNF levels. It’s important to note that in
animal models, the deletion of the BDNF gene don’t enable depressive-like states. This
may be the cause of precise, targeted location deletion of BDNF in certain brain regions.
In inflammatory disease research with rodents, there is an increase in BDNF
concentration levels. A possible theory is that the upsurge in circulating BDNF is due to
BDNF’s function in protecting neuronal structures from further damage (Ha, Kim, Hong,
Kim, & Cho, 2001; Mannion et al., 1999). The extent of the relationship between
peripheral BDNF and diseases and mood disorders is not fully understood. Therefore, the
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need for a better understanding of BDNF variability and the possible therapeutic effects
underscores its role for further research.

13
Statement of the Problem

The primary goal of this study was to evaluate BDNF concentration levels over
the course of 30 days using capillary whole blood samples obtained through finger pricks.
This was important for two reasons: First, resting BDNF levels under normal life
conditions has never been measured over a period as long as 30 days (to my best
knowledge of the published research), so this study provided new information about
normal variability in BDNF levels. A better estimate of normal variability would be
useful in designing studies aimed at examining methods to alter BDNF levels, such as
physical exercise, as variability is a factor in determining statistical power and adequate
sample sizes. The longest duration of BDNF measurement currently reported in the
literature is three days (Dinoff et al., 2016; D’Sa et al., 2012; Szuhany, Bugatti, & Otto,
2015). Second, the most commonly used method for measuring peripheral BDNF is to
use blood from veins (venipuncture). This current study’s method of sample retrieval was
from finger-pricks, which would be a more efficient and versatile method for future
research (Dinoff et al., 2016; Szuhany et al., 2015). Capillary sampling has become
increasingly common in medicine and research due to the process being less-invasive,
quicker and less painful. Obtaining blood samples by finger-pricks rather than by
venipuncture can be especially helpful to stay within blood sample volume limits (Howie,
2011) while still measuring variability.
While it has been long supported that BDNF levels acquired through serum is
100-folds higher when compared to BDNF concentrations in plasma, this difference may
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be due to BDNF being stored in circulating platelets; the platelets act as storage centers
for BDNF (Serra-Millás, 2016). Possibly, tissue trauma and nerve injury activates BDNF
release from these circulating platelets (Radka, Holst, Fritsche, & Alter, 1996). These
sources of BDNF may be a contributing factor to differences in BDNF quantification.
Elfving et al. (2010) conducted a study with recommendations to study BDNF
concentration levels through serum or whole blood since whole blood is more stable for
longer sample storage studies. Different research designs with different methods could be
used to determine if capillary-drawn whole blood BDNF levels are comparable to venous
blood (plasma or serum) BDNF levels, such as obtaining venous and capillary blood
samples at the same time over this longer study duration, but obtaining venous blood was
considered not feasible for the current study. Therefore, I assessed for the variability of
BDNF levels in the capillary whole blood samples under regular life circumstances over
a course of 30 days while also logging their recent physical exercise activity.

Research Hypothesis and Rationale
Hypothesis 1. BDNF concentrations will stay relatively consistent throughout the
course of 30 days, with the overall coefficient of variance (CV) not exceeding 15%.
Rationale for Hypothesis 1. Meta-analyses reveal high variability in
measurements of resting peripheral BDNF levels and of exercise-induced BDNF
increase, due both to methodological heterogeneity and to unknown inconsistencies
(Dinoff et al., 2016). What this study hoped to elucidate is typical BDNF concentrations
under normal life conditions over the course of 30 days. Statistically, having a lower
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standard deviation doesn’t always mean there is less variance. But a CV gives us a point
of reference to assess how spread out the data is. A CV not exceeding 15% of the mean is
proposed as an a priori criteria of stability over time. This criterion matches a level of
variability considered typical at the population level for some quantitative traits such as
intelligence.
Hypothesis 2. We expect to see that recent exercise will significantly increase
BDNF concentration. Average BDNF concentration in samples taken more than 12 hours
after exercise will be significantly lower than average BDNF concentration in samples
taken within 12 hours of exercise.
Rationale for Hypothesis 2. Many previous studies, and meta-analyses, cited in
the literature review above, have shown that voluntary aerobic exercise increases
peripheral BDNF levels in humans and animals within minutes or hours, therefore, I
expect to replicate this finding. Methods vary greatly across previous studies and the
exercise and BDNF sampling methods proposed in this study are within the general
parameters expected to produce effects based on previous studies in humans (Dinoff et
al., 2016). This recent meta-analysis confirmed the association between extended aerobic
(but not resistance) training and increased BDNF levels in blood in humans, but found no
moderating effects of exercise intensity or duration, participant age or sex, or of the use
of blood serum versus plasma, suggesting that the effect is robust and generalizes across
various types of aerobic exercise, participant characteristics, and BDNF measurement
methods. Berchtold, Castello, and Cotman (2010) did a study with mice that revealed that
after an exercise session, BDNF levels remained elevated and returned to baseline 3-4
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weeks after exercise ended. This finding was consistent with their previous finding using
a rodent model (Berchtold, Chinn, Chou, Kesslak, & Cotman, 2005). Though there hasn’t
been a translatable study to assess human BDNF variability and how long BDNF levels
may stay elevated post-exercise. We made the decision to cut off “recent exercise” at 12
hours based on our timeframe of collecting samples. Earliest sample collection began at
12:00 p.m.; therefore, by making the cut-off at 12 hours ago, we were able to
operationalize and categorize the physical exercise to that day of sample collection.
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Method

Participants
Participants were recruited through flyers posted around campus and class
announcements at Humboldt State University (HSU). Due to limited resources prior to
the start of data collection, we were only able to accept, at most,10 participants.
Participants were not offered monetary or school credit to participate. However, they
were offered the option to participate as a co-investigator on the project. As a critical
confidentiality precaution to those who took on co-investigator positions, they were only
allowed to participate in certain aspects of data collection. All participant identifying
information was numerically re-coded and the key was kept confidential with the
principal investigator which permitted anonymous data entry and certain aspects of data
analysis.
As a critical health safety precaution, participants were asked to affirm their selfrated willingness to participate and consent to understanding that the study is asking for
repeated-sampling of up to 300 μl of blood three times a week over a course of 30 days
(refer to Appendix A). Participants were also separately required to reaffirm their health
during each blood draw session, specifically, that they were fit to contribute blood
samples, knew of no reason their blood may be dangerous to others, and knew of no
reasons their own health may be harmed by the blood draw procedures (refer to Appendix
B). Demographic questions included their age, weight, height and most recent sleep
quality (refer to Appendix C). Other selection criteria included non-smoking status, as
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cigarette smoking is known to influence BDNF levels (Collie et al., 2016; Zhang, et al.,
2016). Women were asked about the first date of their most recent menstrual cycle since
hormone cycles are known to influence BDNF levels. Since BDNF levels have been
supported to be highest in the morning with lowest levels at night, these meetings were
always in the afternoon between 12 p.m. and 5 p.m. to minimize confounding effects of
high BDNF levels correlated to circadian rhythm (Begliuomini et al., 2008). Three
participants were excluded due to meeting one or more of the exclusion criteria.

Procedures
This study was conducted at Humboldt State University in Arcata, California
from April 2017 to May 2017. This study and methods were approved by the Institutional
Review Board of Humboldt State University (IRB # 16-164). Following the first meeting,
the investigator(s) met with each participant three times a week up to four weeks total for
repeated blood sampling.
Participants followed their normal routine as the focus of this study was on
natural variability in BDNF levels. Although the participants were not instructed to
participate in a specific exercise regimen, an exercise activity and intensity log was asked
at each session. Specific times of blood collection was chosen by the participant within
the constraints of the protocol and these sessions remained relatively consistent during
each blood-sampling meeting. Meetings took place in BSS 122, where facilities for blood
draws and sample processing were set up (see Appendix D for BDNF collection
protocol).
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Blood draw. All investigators took and received a certificate for an HSU
Bloodborne Pathogen workshop prior to being trained to administer fingertip punctures.
Co-investigators were trained by the PI to use the safety lancets (MediPurpose SLB250)
for ‘finger-prick’ blood collection. Participants were instructed to wash their hands before
each sample collection with lukewarm water and soap to decrease likelihood of infection
and to increase blood flow to the injection site. Single-use hand heating pads were
available afterwards to further promote blood flow to the finger. Participants always sat
down with arm relaxed on an armrest or table at a slight -10 ° to -30 ° angle to assist with
a comfortable blood flow direction. Investigators provided a short hand massage to
promote blood flow to selected fingertip (which was always the middle or ring finger).
The selected fingertip collection site was wiped with a single use 70% isopropyl alcohol
pad prior to puncture and after sample collection. The spring-loaded safety lancet was
positioned and activated to puncture skin just off center of the finger pad, following
manufacturer’s instructions. The first drop was always wiped with a clean cotton pad to
reduce contamination of initial tissue fluid or environmental debris. A minimum of 50 μl
up to 300 μl of blood was collected into a single-use plastic ethylenediaminetetraacetic
acid (EDTA) tube (EDTA, which maintains blood in a fluid state), and the tube was
inverted gently five to 10 times before being placed on dry ice in an insulated ice chest.
Band-Aids were applied to the puncture site after sample collection. Once participants
were dismissed, samples were transported to the Humboldt State University Biology Core
and stored at -80 ℃ prior to being analyzed.
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Sample preparation. Within two weeks of freezing, samples were homogenized
using a homogenization buffer made following manufacturer’s instructions (refer to
Appendix E for protocol) and returned to the -80 ℃ freezer. The manufacturer
confirmed that homogenized blood samples could be re-stored in the -80 ℃ freezer until
ready for plate analysis.
BDNF sandwich ELISA. This study started with two BDNF assay kits (two
plates per kit, four plates total; CYT306, EMD Millipore) which were funded by a
program for interdisciplinary research collaboration run by the Humboldt State
University Dean of Research. Kits were stored in a 2-8℃ until usage. This assay is a
sandwich enzyme-linked immunosorbent assay (ELISA) where BDNF in the blood
samples reacts with molecules in the wells to alter the fluid’s optical density (light
absorbance) in a BDNF concentration-dependent manner. The BDNF plates were read
using the Humboldt State University Biology Core’s microplate reader (SpectraMax i3
Plate Reader, Molecular Devices).
All plates were assayed per manufacturer’s instructions. It’s important to note that
appropriate adjustments were made to the standard serial dilution series in order to
conserve the remaining standard diluent solution for the remaining samples (refer to
Table 1 for standards solution series). One hundred μl of Standards and samples were
pipetted into each well, sealed and incubated at 2-8℃ overnight. Using a multi-channel
pipet, 250 μl of diluted Wash Buffer was pipetted into each well. The fluid was removed
by inverting the plate over a sink and gently flicking the fluid out of the wells and
followed by blotting the plate on clean paper towels. This process was repeated five to six
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times in order to thoroughly wash the plate to reduce background noise. One hundred μl
of diluted biotinylated mouse-anti-BDNF monoclonal antibody was added into each well.
The plate was sealed and incubated at room temperature for 3 hours on a shaker and then
the wash step was repeated. This was followed by 100 μl of diluted streptavidinhorseradish peroxidase conjugate solution. The plate was sealed and incubated at room
temperature for one hour on a shaker. The plate was washed again following wash
instructions. TMB/E was warmed to room temperature and 100 μl of the TMB/E was
added into each well and the plate was incubated at room temperature for 15 minutes.
The solution achieved a range of blue colors. To stop the reaction, 100 μl of Stop solution
provided in the kit was added into each well which caused the blue color to turn yellow.
The plate was immediately read at 450 nm.
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Table 1
Standards Dilution Series
Standard Number

#1

#2

#3

#4

#5

#6

#7

0 Dose

Initial Volume (µl)

475

250

250

250

250

250

250

250

Concentration (pg/ml)

1000 500

250

125

62.5

31.25 15.63 0.0

Note. This study adjusted the Standard Curve volumes to allow for maximum
preservation of the kit’s standard diluent to dilute blood samples. Standard curve volumes
were decreased in half from the default instructions and appropriate changes were made
with the stock standard solution (25 µL) to provide the same strength (1000 pg/ml).
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Due to insufficient literature on dilution procedures for capillary-drawn whole
blood, we ran a preliminary plate analysis with the first plate to find a proper dilution
series. Samples with larger volumes were chosen for the dilution series to provide
preliminary data and still have enough volume left for subsequent analysis. Previous
BDNF ELISA studies have diluted whole blood samples at 1:50, 1:200, and 1:500
(Elfving, Plougmann, and Wegener, 2009). But, for the purpose of this study, in order to
find the lowest possible dilution and conserve the maximum amount of the kit's sample
diluent solution, we utilized the first plate to obtain preliminary data on possible dilution
ratios. Samples were analyzed at full concentrations to observe undiluted optical
readings; other samples were diluted with the sample diluent at 1:1 and 1:3 dilutions
(refer to Figure 1 for Plate One’s data).

24

Figure 1. Plate One Assay. A representative chart displaying Plate One’s standard curve
(shown with a blue trend line on bottom left). The standard curve is an average from
duplicated standards with a r2 = 0.996. Optical density (OD) is the amount of light that is
absorbed by the sample. All dots represent a data point. All data points above the 1.5 OD
were samples at full concentration. All points below the 1.5 OD were samples either at
1:1 or 1:3 dilution.
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Plate One’s results produced absorbance readings outside the limit of detection
(too high). We contacted Millipore, and Millipore agreed to send us a new replacement
kit. While waiting for the new kit to arrive, we used the remaining plate from the first kit
(Plate Two) to do a second dilution series including a 1:25 and 1:50 dilution (e.g., one
individual sample was plated in duplicates at the 1:25 and the 1:50 dilutions in order to
compare dilution readings.) As a manipulation check, we also analyzed possible
background noise by plating sample diluent from four clean EDTA tubes. Absorbance
readings confirmed that 1:50 dilutions fit within the standard curves the best.
For Plate Three, homogenized samples were plated as follows: samples were
removed from -80 ℃, thawed on ice, then centrifuged at 3000 x grpm for 1 minute. Two
microliters of the sample were pipetted into an Eppendorf tube with 147 μl of sample
diluent. Diluted sample was vortexed for a few seconds then returned to ice. One hundred
μl of freshly diluted sample was added per well on a 96 well plate, with 16 wells reserved
for the plate standards. It’s worth mentioning that while all samples were tested in
duplicate, the duplicates were tested on different plates. This decision served a dual
purpose: 1) to maximize preliminary analysis output data and 2) to determine if certain
samples needed to be analyzed for a triplicate run since the dilution series in this protocol
experimented with a 1:50 sample dilution series. This aided in careful preliminary data
review and provided invaluable insight for the next sample plating. For the purpose of
this study, sample concentrations that fell below or above the limit of detection (highest
and lowest point on each plate’s standard curve) were not included.
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After preliminary analysis of the data from Plate Three, we realized that an error
was made, specifically, an old solution from the first kit was used during the plateprepping phase. This may have resulted in the standards having very low BDNF
concentration values. So, we called and received a second replacement kit from the
manufacturer. In order to streamline the plate processing time, we diluted samples ahead
of time, refroze them and thawed them to be used on Plate Four. But, with this protocol
change we experienced yet again another poor plate reading with the concentrations
being outside the limit of detection. After contacting the manufacture for a third time,
they agreed to send out a new replacement kit. For the purposes of organization, this
study ended up with eight total plates which were referred to as Plates One through Eight,
labeled according to the order processed. This study went through four preliminary plate
readings which produced unusable but insightful data for protocol adjustments on the
remaining plates. Out of eight total plates, the final dataset came from samples that were
assayed on plates Five, Six and Seven (refer to Appendix F for final BDNF assay
protocol). Generally, each of those plate’s standard curve included seven points with a
correlation coefficient of r > .99 (as shown in Figure 2).
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Figure 2. Representative Standard Curve. A representative seven-point standard curve for
Plate Seven’s whole blood BDNF ELISA. This curve was obtained using duplicate
BDNF standards in the Millipore Chemikine BDNF ELISA and produced a correlation
coefficient of r = .999. Only data within each plate’s standard curve can be quantified and
used.
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Data analysis. Statistical analyses were performed using R 3.4.3 software (R
Core Team, 2017; see Appendix G for R script). A coefficient of variance analysis
assessed the overall within-subject variability (standard deviation) in BDNF levels
against the overall mean. In addition, a linear mixed-effects model analysis was
performed to assess BDNF concentration levels between those who recently exercised
within 12 hours and those who didn’t. This analysis is robust to both skewness and
kurtosis and handles multiple sources of variance, especially those from repeatedmeasures (which is not possible with a traditional ANOVA) which allows for the use of
both continuous and categorical data as predictors (Baayen, Davidson & Bates, 2008).
This analysis doesn’t give a probability value to determine the statistical significance of
the model in order to reject or fail to reject the null hypothesis. But, in order to obtain a
significance value, we performed a likelihood ratio test that compared the fixed effects
and random effects against a model with only the random effects to understand what
variance that can be attributed to the random effect variable. Three data points were
missing due to the troubleshooting phases with Plates One through Four, which depleted
the samples entirely; therefore, the final data set from plates Five, Six and Seven were
missing those three daya points. Therefore, data imputation using predictive mean
matching (PMM) was performed through the R package “mice” (van Burren, 2011).
PMM helps to estimate a linear regression and uses data from a multivariate normal
distribution. Values were generated for both missing and non-missing data and used to
fill in the three missing values. In particular, for each of the missing values a predicted
value is generated and is as close to a prediction of what the missing data may have been
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based on the other data points. Typical cases have five imputation values with five
iterations each. Three observations were missing from the initial analysis and a series of
10 iterations and 50 imputations were utilized to fill in the missing data points. The final
analysis utilized the dataset with three imputed data points out of 108 total data points.
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Results

Stability of BDNF Over Time
The final cohort of participants were healthy volunteers (N = 9; 5 female) from
Humboldt State University between the ages 18 and 39 years with a mean age of 27.88 ±
7.04 years and a mean BMI of 23 2.9 kg/m2. Samples were duplicated and assayed on
separate plates (each of the sample duplicate was assayed on a separate plate and the
average of those two concentration values were used). All samples were duplicated and
assayed on Plate Five through Seven fell within each plate’s standard curve; therefore,
their sample averages were used in the final dataset. The overall coefficient of variance
(CV = .19) failed to meet our a priori stability over-time criterion (refer to Table 2).
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Table 2
Participant Average BDNF Measurements over 4 weeks, Mean, Standard Deviations and Coefficient of Variances

ID

1

2

3

4

5

6

7

8

9

10

11

12

M

SD

CV

5.82

0.16

1

35.32 48.03 33.03 34.40

33.15

35.28

38.38 43.60 29.63 30.26 44.86 36.23 36.84

2

47.43 55.25 25.61 21.41

40.03

43.25

33.38 49.20 33.03 26.83 40.64 39.64 38.42 10.23 0.27

3

36.88 36.64 33.47 21.72

26.56

28.39

25.26 24.22 21.30 24.37 28.75 28.72 28.02

5.27

0.19

4

22.33 25.33 26.11 19.22

18.87

13.06

21.66 28.42 20.83 21.41 22.65 23.68 22.00

3.95

0.18

5

19.24 13.56 11.14 15.59

15.07

15.35

14.60 16.39 10.86 12.21 16.02 14.67 14.60

2.36

0.16

6

29.99 34.31 29.84 28.30 35.045

46.36

19.17 26.35 29.47 28.59 31.75 22.73 30.20

6.75

0.22

7

37.53 56.51 48.45 35.24

27.09

29.535 26.87 34.58 30.23 46.36 19.59 30.23 36.00 10.50 0.29

8

41.76 27.03 31.54 33.37

33.5

37.75

31.66 33.04 37.09 38.42

9

35.76 27.98 29.45

29.97

21.69

32.55 34.64 28.54 28.09 32.53

28.7

27.7

31.80 33.72
36

30.50

4.35

0.13

4.06

0.13

Note. M = Mean; SD = Standard Deviation; CV = Coefficient of Variance. All values including M, SD and CV are
measurements in pg/ml. The a priori CV was set at 15% as a method to assess stability over time. The CV is calculated as
follows: SD/M. While some individuals did fall within this a priori CV, the current data indicates an overall CV = 19%. The
overall was M = 29.80 (SD = 5.92).
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Relationship of Individual Characteristics to BDNF Levels
Initial data inspection of histogram plots did not reveal any obvious deviations
from normality (as seen in Figure 3). But, further statistical analysis used to examine the
relationship between BDNF levels and recent physical exercise utilized a linear mixedmodel analysis.
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Figure 3. Data Distribution. Duplicated BDNF blood samples (N = 105) were assayed.
Data did not present any obvious deviations from normality. Averages of assayed
duplicate samples were used in the final statistical analyses.
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The R package lme4 (Bates, Maechler & Bolker, 2012) was used to perform a
linear mixed effects analysis of the relationship between repeated-measures BDNF levels
and recent physical exercise. Recent exercise history was entered into the model as a
fixed effect, and participants were entered as random effects. Fixed effects are factors
that are constant and defined. Random effects are factors that are random samples of
possible levels. In this case, the participants are random selections from the larger
population. Probability values were obtained by likelihood ratio tests of the full model
with ‘Exercise Response (Yes/No)’ against a model with just the participants to assess
the variance with and without the fixed effect (refer to Appendix H for linear mixedeffect output). While samples taken after recent exercise had a higher median (Mdn =
32.14) and wider range overall, the likelihood ratio test no significant differences in
BDNF levels between the group of post-exercise samples and the samples not associated
with recent exercise χ2(1, N = 9) = 2.28, p = .13. This analysis had an effect size of R2 =
0.57 (refer to Figure 4 for exercise response distribution).
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Figure 4. Exercise Response and BDNF Levels. Each dot is a data point with darker dots
represent overlapping data points. Exercise responses to recently exercising within 12
hours of sampling session: 1 = “yes” and 2 = “no.” Visual inspection displays a larger
range of BDNF levels for those who reported “yes” to recently exercising (M = 32.75, SD
= 8.93) when compared to those who reported “no” to not having recently exercised
within 12 hours of the sampling session (M = 27.66, SD = 9.40). However, these results
are not statistically significant.
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Targeted post-hoc analyses were performed to obtain a better understanding of
BDNF concentration variability: self-reported exercise intensity, BMI, gender, female
menstrual cycling. Participants reported exercise intensity level on a 4-point ordinal scale
(none, low, moderate, high) at each sampling time. We grouped exercise intensity into
these categories based on the literature that suggests that self-selected intensity
preferences have been associated to higher BDNF levels (Keinan et al., 1999; Williams et
al, 2016). Because we didn’t measure exercise intensity levels, this was our way to assess
the relationship between them. I analyzed the relationship of exercise intensity to BDNF
concentration using a linear mixed effects analysis with exercise intensity as a fixed
effect and participant as a random effect (refer to Appendix I for linear mixed-effects
output). Probability values were obtained by likelihood ratio tests of the full model with
exercise intensity in question against the model without exercise intensity. There was no
significant difference between intensity types and BDNF levels χ2(3, N = 9) = 5.22, p =
.15. This model had an effect size of R2 = .57 (refer to Figure 5 for a plot illustrating the
fluctuating mean BDNF levels of each intensity response).
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Figure 5. Exercise Intensity and BDNF Levels. Plot showing mean BDNF levels of each
self-reported exercise intensity at each blood draw session over the 12 blood-draw
sessions. Responses were based off a 4-point ordinal scale (none, low, moderate, high).
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Correlation analysis showed that BMI was not correlated with BDNF
concentration levels r(7) = .06, p = .50. BDNF levels were not significantly correlated
with gender r(7) = 0.27, p = .18, d = 0.27. An ANOVA was done to analyze female
BDNF concentration levels during Follicular phase (days 1-13) and Luteal phases (first
stage: days 13-21 and second stage: days 22-29) of the menstrual cycles. BDNF levels
were not significantly different during the Follicular and Luteal phases F(1, 4) = 0.16, p =
.68, partial η²=.004.
Lastly, a post-hoc time-series analysis was done to obtain a better assessment of
BDNF variability between participants (refer to Figure 4). Time-series analysis are used
in exploratory analysis for evaluating and predicting future trends within a time frame.
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Figure 6. Time Series Analysis. Graph depicts a time-series plot of BDNF concentration
levels for each participant taken three times a week over 4 weeks. Each line represents a
different individual with varying ranges of BDNF concentration levels (Min = 10.86
pg/ml, Max = 56.51pg/ml). Individual coefficient of variance displayed next to each
participant key.
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Discussion

BDNF Variability Over Time
In order to understand BDNF variability under naturalistic conditions, this study’s
primary objective was to track those levels over the course of 30 days. An a priori
criterion was set for a stability baseline prior to investigating. This criterion was practical
way to frame and set up a stability measure in order to evaluate BDNF variability. Our
results show moderate BDNF variability within participants (CV = .19) which did not
meet our a priori criterion (CV = .15) and there were high within-subject variability (refer
to Appendix J for each participant’s individual variability scores). However, having the
mere variability quantification is equally important. Because variability influences the
statistical power, understanding the naturalistic variability underscores its importance for
future methodology designs. Having an estimate of variability is a useful benchmark for
assessing the statistical power of future studies on BDNF health effects and is
fundamental to interpreting findings of other BDNF related studies.
Two crucial components in this study was a longer time span and studying BDNF
concentration levels through whole blood. Although D’Sa et al. (2012) studied BDNF
through serum over three days and found no significant day-to-day differences between
the serum BDNF levels. The type of blood sampling and time span may have been a
reason for why our results had such a high variability. The data from these assay kits did
produce BDNF concentrations that are within range to other BDNF levels measured in
other studies (Dinoff et al., 2016; Elfving et al., 2010; Klein et al., 2011; Trajkovska,
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Marcussen, Vinberg, Hartvig, Aznar & Knudson, 2007) ultimately, underscoring how
important it is to understand normal BDNF variability and the potential of studying it
through whole blood. Timing of sample collection is important as well. We tracked
BDNF levels over 30 days from April to May and this may have introduced new
variables that may have affected the concentration variability such as changing exercise
routines (gearing up training for nationals/championships), increasing mental stressors
leading up to finals week and environmental factors in preparation for life postgraduation.

Exercise and Individual Differences Related to BDNF Levels
A secondary objective of this study was to investigate how recent physical
exercise can affect BDNF concentration levels. New research still show evidence that
short bouts of physical exercise increases BDNF levels (Tsai, Ukropec, Ukropcová, &
Pai, 2018). The duration of these increases have been supported in a research which
showed that platelets circulate in the peripheral blood for up to eleven days but BDNF
proteins in plasma only circulates for up to an hour (Kishino et al., 2011; Poduslo &
Curran, 1996). In animal models, BDNF has a half-life of 10 minutes in the blood and
then removed from the circulation by the liver (Sakane & Pardridge, 1997). In order to
better understand BDNF levels in human whole blood, assessment of BDNF levels after
delayed physical exercise (within the past 12 hours) is a novel approach to operationalize
and understand how BDNF levels may fluctuate on a daily basis. Because circadian
rhythms can influence BDNF levels, we used this criteria in order to stay within the
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standard 24-hour day since our earliest sample collection began at 12:00 noon each day.
With this cut off, we found no statistical differences between samples post-exercise and
samples from those who didn’t recently exercise.
The environmental condition of this study was to investigate BDNF concentration
levels under normal life circumstances. We wanted to minimize the amount of control
we had on exercise regimens. While categorized exercise intensity levels based on a fourpoint ordinal scale based on the literature that self-selected intensity levels may be
associated to higher BDNF levels (Keinan et al., 1999; Williams et al, 2016). However,
we didn’t provide a guideline as to what may be considered low, moderate or high
intensity. A study performed by Pareja-Galeano et al. (2015) had controlled variables and
exercise protocols, but these conditions don’t typically translate to normal life
circumstances. Perhaps future studies should consider operationalizing exercise
regimens/intensity levels and investigating carry over effects to understand normal life
BDNF variability post physical exercise activity. In addition, sampling multiple fluids
simultaneously (plasma, serum, whole blood and saliva) at different time points postexercise -- e.g., BDNF measured from capillary blood, venous blood, and saliva, at
multiple points throughout the day -- would provide a more relevant measurement of
BDNF variability.
Moreover, there are numerous factors mentioned in this study that may also affect
BDNF levels, including circadian rhythms, hormonal cycling, sunlight exposure, genetic
make-up, BMI, physical exercise history and mental health. In this current study, it is not
likely that diurnal variation contributed to the observed variance since all samples were
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collected at a common time for each participant at each session. Some literature suggests
BDNF concentration levels in normally cycling women vary depending on the phase of
the menstrual cycle (Pluchino et al., 2009). While there is evidence supporting different
BDNF levels between gender (Lommatzsch et al., 2005; Pluchino et al., 2009;
Trajkovska et al., 2007), we found no statistically significant differences between BDNF
concentration levels of sex and the different phases (Luteal and Follicular) of the
menstrual cycle.
Factors such as genetic background and mental health history also may have
contributed to individual variances between BDNF levels. These effects need further
examination. For example, healthy populations at risk for mood disorders and depressed
patients have lower serum BDNF levels that correlate with the severity of their disorder
(Karege et al., 2002). Genetic variants are a crucial factor when assessing BDNF levels.
Future studies involving capillary-drawn whole blood should consider obtaining thorough
genetic BDNF information, as well. Developing a protocol to assess natural BDNF
concentration levels in participants with the Val66Met polymorphism may aid in the
investigation if of BDNF variability between populations with and without this
polymorphism.

Methodological Limitations
The biggest limitation was sample size. Due to timing, resources and funding, this
study was only able to evaluate BDNF concentrations from 9 participants. These
participants were between the ages of 18 and 39 years with a mean age of 27.88 ± 7.04
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years. If our results were generalized in anyway, it’s important to consider that our
participants were within a limited age range. Not to mention, they averaged a mean BMI
of 23 2.9 ± kg/m2. This participant pool consisted of one HSU athlete and physically
active participants. While they were healthy adults, this sample may not have been a
representative sample of the general population.
Moreover, our initial resources included two assay kits, each with two 96 well
plates (192 wells/kit) for roughly $420 each/kit. Sixteen wells are reserved on each plate
for running standard curve solutions. Recruiting 10 participants to contribute up to 12
samples each yields 120 samples. Samples are recommended to be assayed in duplicates,
at minimum, which would require three plates. Because this protocol required at least one
plate to be used to test a dilution series, this meant that obtaining more participants was
not feasible for this study. A post-hoc power analysis was conducted in order to
understand how many participants would be necessary to have 80% power for detecting
an effect size of 0.8, the study would require 222 participants in each group (exercise vs.
no exercise). Thus, sample size was a huge limiting factor and contributed to an
underpowered study.
In order to properly account for the post-hoc power analysis’ minimum sample
size in turn to achieve the desired effect size, it would require at least 122 plates (60 kits,
estimated to cost ~$25,200) to be sufficient to analyze 12 duplicate samples from each
participant. This is in addition to having additional resources for making homogenization
buffers and sample diluent solutions. The minimum recommendation is to assay samples
in duplications; but, it is highly recommended to run samples at triplicates or by serial
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dilutions to allow for a more thorough sample assessment. More samples would require
more personnel in general, in order to hold more blood-draw sessions. All coinvestigators would need proper Bloodborne safety and finger-prick training. Scheduling
and re-scheduling blood draw sessions were a recurrent theme in this study. Therefore, to
increase the volume in sample size brings other variables that this study just simply could
not handle.
Another potential source of laboratory error related to the sampling method used
is the possibility of hemolysis from excessive squeezing or massaging of the fingers,
which may have been done to encourage blood flow. While co-investigators were trained
and cognizant that these procedures are not recommended (Lenicek Krleza, Dorotic,
Grzunov & Maradin, 2015), it could have contributed to the large variance between
duplicate samples because BDNF within broken cells degrade quicker (Trajkovska et al.,
2007). BDNF concentration levels were highly variable between participants, which is
consistent with this possibility.
There were numerous technical limitations that had to be taken into consideration.
Timing of sample homogenization is extremely crucial to avoid samples from further
degrading. For example, the samples went through numerous freeze-thaw cycles after
homogenization. Trajkovska et al. (2007) found that whole blood can be thawed up to
three times without compromising its BDNF concentrations. They also found that
repeated freezing cycles at a minimum storage of -20 ℃ decreased serum BDNF
concentrations but not whole blood BDNF concentration. This finding suggests that
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platelets protect BDNF from further degradation. This current study homogenized whole
blood samples within two weeks of obtainment and stored the homogenized samples at
-80 ℃ for six months. Therefore, our samples are not likely to be affected by physical
storage or freeze/thaw conditions.
In addition, changing protocol steps may have contributed to the inconsistency in
BDNF concentration levels and increased inter-plate variance. For example, this study’s
protocol assayed duplicates samples on separate plates. This decision was made to due to
the initial resources (four BDNF plates) and time constraint in order to provide
preliminary dilution series data. While we understood that duplicates are typically
assayed on the same plate, due to our resources, this decision was intended for us to
dilute samples and rerun samples at a larger dilution, if necessary, for a triplicate run
should they fall outside the standard curve during the first two dilutions. In addition,
when we processed Plate Six, the manufacturer’s sample diluent was running low. We
obtained the sample diluent recipe from Millipore and made a new solution in-house. A
manipulation check was performed on randomly selected samples (n = 9) that were
diluted with the manufacturer’s sample diluent and the new solution. This number was
chosen due to the amount of wells we could spare to perform the manipulation check.
This change in solution can be expected to add to measurement noise. When using the kit
solutions from the same batch and pipetting techniques are consistent, there would likely
be less varriance between sample values.
Since technical factors such as method, preparation, analysis and storage of blood
samples are crucial in BDNF concentration quantification, it could be difficult to produce
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and replicate data. Perhaps a protocol modification to consider is to aliquot undiluted
samples into separate vials intended for specific plates in order to reduce freeze/thaw
cycles, contamination and degradation. This may help to obtain more within- subject
reproducible BDNF concentration values with less variance. However, it’s worth noting
that most of the above-mentioned concerns are sources of error that would be expected to
increase BDNF variability, so our measure of an overall CV of 19% is likely to be overestimate within-subject BDNF variability. On the other hand, factors such as cell damage
during collection that could degrade BDNF in the sample before the detection assay is
processed could decrease variability by causing a floor effect on measurements. But since
all readings were above the detection threshold shown by the assay’s standard curve, this
such a floor effect seems unlikely.

Relationship Between Brain and Peripheral BDNF Levels
The current study analyzed peripheral BDNF as a proxy for brain BDNF levels,
but the relationship of brain and peripheral BDNF concentrations is not entirely clear, so
caution is required for interpreting the relevance of these findings to the construct of main
interest, which is BDNF’s positive effects on brain and cognitive health. Findings from
an animal study conducted by Klein et al. (2011) suggests that BDNF concentrations in
blood and plasma are comparable to BDNF concentrations in the hippocampus, which
warrants using peripheral BDNF as a biomarker. However, other animal studies indicate
different levels of BDNF in different regions of the brain (Krishnan et al., 2007). Radka
et al. (1996) did a study that involved rodents and humans and showed that there was
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higher plasma BDNF concentrations in rodents when compared to humans. A possible
explanation includes the locale of sampling from the rats’ trunk after decapitation
compared to humans’ peripheral blood sampling. There is support that BDNF crosses the
BBB in both directions (Pan et al.,1999; Poduslo et al., 1996), but there are other
explanations and sources of peripheral BDNF release such as liver, smooth muscle cells,
and endothelial cells (Ernfors, Wetmore, Olson, & Persson, 2000; Nakahasi et al., 2000;).
It is not entirely clear that peripheral BDNF concentrations reflects levels of BDNF
released from the CNS.

Future Directions for BDNF Research
Existing evidence supports physical exercise as a mechanism to up-regulate
BDNF concentration levels, in turn, improving mood and cognitive function (Zoladz &
Pilc, 2010). Aerobic exercise training has been supported over and over with
improvements in attention, memory and executive functioning, although not working
memory (as reviewed by Smith et al., 2010), whereas, Wang and Wang (2016) showed
that low intensity treadmill exercises could improve short-term working memory. Van
Dongen, Kersten, Wagner, Morris, & Fernandez (2016) showed that participating in
physical exercise after a period of learning can actually increase memory recall which is
consistent with hippocampal activation during memory retrieval. But it is still unclear
how these mechanisms directly affect BDNF secretion and concentration (Campos et al.,
2016). Thus, there is demand for a standardized and systematic approach across studies to
measure BDNF levels and how physical exercise can affect them (Knaepen et al., 2010).
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The prevalence of BDNF-related physiology research is to understand the
molecular underpinnings of BDNF as it can be a crucial component for insight into the
genetic disparities and possible therapeutic avenues. A breakthrough study by Egan et al.
(2003) found that the BDNF polymorphism gene Val66Met was linked to poorer memory
recall and atypical hippocampal activation. Such studies help to provide understanding
and justification for animal research since we currently rely on animal models to support
the value of conducting clinical trials for humans. Subsequently, molecular studies in
humans help to provide a more genetically personalized treatment for brain or behavioral
changes due to the high sources of variability. Research studying how physical exercise
affects BDNF concentration levels help to provide an empirical basis for therapeutic
interventions.
While animal research has shown that neural stem cells within the subgranular
zone continue onto adult mouse neurogenesis (van Praag, 2002), there has been some
recent push-back on a central premise of BDNF’s beneficial effects, namely, that
increasing BDNF can increase the rate of neurogenesis in adult brains. Sorrells et al.
(2018) found evidence that young neurons begin to decline in the dentate gyrus during
infancy and continues to decline onto early childhood. There was no evidence of young
neurons or diving cells in adults with epilepsy and the control group. If any was seen in
the control participants, it wasn’t notably significant. While it was found that
neurogenesis happens postnatally in macaques, in adult macaques (17 and 24 years old),
there was little to no evidence of young neurons. These evidences propose that the
presumed BDNF-linked neurogenesis may not be real at all. This suggests that most of
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the literature on BDNF from animal models don’t fully translate to the human species.
Feasibly, this is a motivation for more continued research to understand the function of
BDNF in humans. For example, while BDNF may not control the birth of new, young
neurons in adult brains, it may still influence cognitive health by promoting healthy
functioning of existing neurons.
Problems related to inconsistent research methods and underpowered studies
make conclusions difficult. BDNF research is easier in animal models and are more
difficult with human participants. Since we currently have to assess BDNF through
peripheral methods, a standardized protocol is needed for measuring human blood BDNF
levels since there is such inconsistency between serum, plasma, platelet, whole blood,
coagulated or anticoagulated blood forms (Knaepen et al., 2010; Trajkovska et al., 2007;
Sanchis-Gomar & Lippi, 2014). Not to mention, different components (i.e., serum,
plasma, whole blood, and platelet count) that have been studied from the same participant
still end up with varying results depending on sample type (Pareja-Galeano et al., 2015;
Trajkovska et al., 2007). An important distinction is that whole blood must be lysed
before being plated so this adds an extra step where confounding variables could be
introduced. For example, Karege et al. (2005) found a non-significant difference between
whole blood BDNF levels in depressed participants when compared to the controls.
However, their serum BDNF concentrations in depressed patients were lower when
compared to their controls, perhaps, due to BDNF’s mechanism of release. Thus, more
research is needed to understand the locale and timing of peripheral BDNF retrieval.
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While this study worked within the constraints of its limitations in attempt to
provide a fuller picture of BDNF variability over time, it still remains unclear if there are
valid cognitive benefits link to BDNF. Perhaps, understanding human BDNF variability
can be a start and be used as a benchmark for designing and interpreting future BDNFrelated studies.
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Appendices

Appendix A: Consent to Participate

Purpose of the study:
The aim of this study is to assess how levels of a protein, called brain-derived
neurotrophic factor (BDNF), vary over 30 days in blood samples drawn from ‘finger
prick’ safety lancets. BDNF is a protein that is found in your body and nervous system
and is important for brain health. We hope to learn more about BDNF by examining
levels over a longer time period than has been examined before.
What we are asking our participants to do. Your involvement in this study to
completely voluntary and you can quit at any time. However, to get the most reliable
results possible, we hope our participants will meet with us to contribute a ‘finger-prick’
blood sample 3x a week for up to 30 days, for a total of 12 samples. In addition, since
BDNF levels are linked to exercise, we will ask you about your most recent physical
exercise routine at each session. But, we are not asking you change your physical
exercise habits in any way, just to report the time and intensity of your last exercise. We
are asking your permission to contact you periodically by email or cell phone during the
30-day study to arrange the timing of meetings.
Procedure and time line of the study.
At the first meeting, you will be asked to fill out a brief health screening form and to sign
this consent form. Then, for three times a week, you will be asked to meet the
investigator (Sally Hang), at your convenience within the constraints of the study, for
about 10 minutes to do three things: (1) answer a blood collection readiness question (2)
contribute a blood sample (3) answer questions about the time and intensity of recent
exercise.
Information about the blood collection methods.
A spring-loaded ‘safety lancet’ will be used to puncture skin at the fingertip and produce
a few drops (50 - 300 μl) of blood that will be collected into a plastic tube. For most
people, this results in mild discomfort lasting a few second to a minute. The following
steps will be taken for safety and comfort
- The principle investigator, Sally Hang and responsible co-investigators, will have
completed a blood-born pathogen safety training class
- Investigators will always wear new, nitrile gloves with each participant
- Participant will wash hands prior to each session with Luke warm water and soap
for at least 20 seconds
- Investigator will perform a gentle palm massage to promote blood flow
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-

Your skin will be wiped with an alcohol pad before and after collection
Your fingertip will be pricked using a safety lancet
You may prick your own finger if you prefer
A heating pad will be available to promote blood flow in your finger
Band-Aids will always be applied after blood collection and a first aid kit will be
available onsite
Contact information for the HSU Health Clinic, local hospitals, and Counseling
and Psychological Services (CAPS) will be readily available for participant's use
should an emergency occur.

Risks, Benefits, and safety measures:
Confidentiality.
Your blood samples and questionnaires will be labeled with a numerical code and will
never be directly connected to your name. Only the principle investigator will have a key
linking your name to your code number and she will keep it secure and confidential.
Blood sample handling.
Your blood samples will be stored securely at HSU. Your blood will be tested only for
BDNF; no other tests will be done. Your sample will be safely disposed of after testing,
which will be no more than 1 year after collection.
Risks and safety measures.
Possible risks from blood collection include dizziness and the rare possibility of light
headedness or injury from bleeding. Although the risks are small, we will have a first-aid
kit on hand if needed. You will be asked to affirm your readiness for the blood collection
before each collection. As noted, alcohol disinfectant wipes and gloves will be used to
reduce the risk from pathogens.
Benefits.
You may directly benefit from your involvement in this study by choosing to become a
co-investigator on the project. Becoming a co-investigator is an option open to all
participants and includes the opportunity to participate in analyzing and interpreting data
and, potentially, presenting results. Co-investigators will have to complete a human
subjects training course and receive IRB approval before beginning work as an
investigator. Indicate below if you would like to be a co-investigator in this study and
Sally will contact you with more information.
Voluntary participation.
Your participation is voluntary and you may also withdraw from the study at any time
without jeopardizing your position as a co-investigator if you choose to be one.
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Contacts:
If you have any questions about this study you may contact the investigator, Sally Hang
at sh1738@humboldt.edu, or the faculty supervisor, Ethan Gahtan, at
eg51@humboldt.edu or 707-826-4545. If you have any concerns with this study or
questions about your rights as a participant, contact the
Institutional Review Board for the Protection of Human Subjects at irb@humboldt.edu or
(707) 826-5165.
By signing below, you consent to participate in this study.

Signature______________________________________________Date______________

(Check and initial if applicable) I would like to be a co-investigator on the project ______
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Appendix B: Health Reaffirmation at Each Session

Date: _________________

1. Do you feel well and healthy enough today to contribute a blood sample? Yes/ No
2. Did you recently exercise? Yes/ No
If yes, please answer the following?
a. Date: _____________________ Time: _____________________ A.M. / P.M.
b. Type of Physical Activity: _________________________________________
c. Intensity of Physical Activity: Low / Moderate / High
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Appendix C: Demographics
Name: _________________________________________________________________
Sex:

M

F

Age: _________

1. Do you use Tobacco? Yes. No.
If yes, how many packs a week? _______________________________________
2. Are you generally in good health? Yes / No
3. Do you exercise regularly? Yes/ No. If yes, for how long? ______________________
month/years
4. What is your main form of exercise (e.g., biking to school, walking, running, cycling, weight
lifting, high intensity interval training (Hiit), walking across campus…etc):

5. Do you know of any reason why your health might be harmed by the procedures
described for this study? Yes / No
6. Do you know of any reason why your blood might be dangerous to others? Yes/ No
7. Typical hormone cycles in females are known to influence BDNF levels. To control
for that in the study, if you are a female with typical hormone cycling, please estimate the
first day of your current cycle: ________ days ago / Not Applicable
8. Please estimate your height _________ and weight _________, as these factors may
also be related to BDNF levels.
9. Please rate your general sleep quality over the previous month from 1 (poor sleep over
the past month) to 10 (excellent sleep over the past month): 1 2 3 4 5 6 7
8 9 10
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Appendix D: Blood Draw Protocol
Note: this protocol was adapted from a similar protocol shared with the investigators by
Chris Benassi, Trevor Caudle, Thomas Williams (all HSU Alumni) and Tina Manos
(HSU faculty). Some of the wording is unchanged from the original protocol.
Testing Supplies:
•
•
•
•
•
•
•
•
•

Single Use Safety Lancets (referred to as ‘finger prick devices’ in the protocol
application)
Disinfecting 70% isopropyl wipes (alcohol prep pads)
Cotton Squares
Band Aids & First-Aid kit
Biohazard disposal container with hard shell, lined with biohazard bag and nonpenetrable lid.
Disposable, sterile, absorbent pads for covering table surfaces during blood draws
and blood handling.
Separate biohazard bag for table covering pads
Nitrile exam gloves
300 µl SAFE-T-FILL® Capillary Blood Collection Tubes with EDTA for blood
collection and storage

General Safety:
•
•
•
•
•
•
•
•
•
•

All persons (Sally Hang and responsible co-investigators) administering blood
collection must have current Hepatitis B vaccine.
All researchers participating in blood collection must have proper Blood Borne
Pathogen (BBP) training.
All tests are to be treated as potentially infectious.
Hands should be washed with soap and warm water. If a glove is ripped, hands
should be washed and gloves changed before continuing to collect blood. Hands
should be washed thoroughly after removal of gloves.
Dump used lancet, cotton square, capillary tube, into biohazard container
immediately following use.
The blood collection table will be set up within 50-meters of a hand-washing
facility.
Eating or drinking is prohibited in testing area.
In case of an Emergency Call 911 then Administer First Aid.
Sterile absorbent pad will cover the blood collection table in order to absorb any
blood spills on the table. A new pad will be used for each participant.
Protective clothing must be worn by persons administering test including:
o Nitrile Gloves

73
o Laboratory Coat
o Safety Glasses
o Closed Toe Shoes

Management of Accidents and Injuries:
First, attend to any injured personnel. Cell phone must be present. Call 911 for
emergency assistance and inform responders of biohazards that may be a threat. Notify
the faculty supervisor and complete an incident report form at the soonest possible
opportunity.
Accidents that may occur include the following:
• Fainting- A subject may become dizzy of faint from the sight of blood. If this
occurs, move the subject into the supine position with their legs slightly elevated.
Make sure to keep up communication with subject in order to assure proper
recovery.
• Hematoma- May occur either when the needle has penetrated through the vein or
when insufficient pressure is applied on the puncture site immediately following
test. The puncture area will swell and become discolored. If this occurs, apply
firm pressure directly on the site for 5 minutes.
• Needle-Stick Injuries- May happen to either the subject or the tester and is
classified by any puncture injury caused by exposed lancets or any other sharp
object. Extreme caution is advised. If injury does occur, wash wound immediately
with water and treat with 70% isopropyl alcohol.

Exposures and Needle-Stick Injury:
•
•
•
•

Although fewer than 0.3% of HIV-infected needle sticks lead to cross infection,
this possibility should be known to blood collection staff (Sally Hang) prior to
involvement in blood handling.
Report exposures and/or needle-stick injuries verbally to the UPD responders.
Suspected exposures should also be reported.
Report the exposure and/or needle-stick to the EH&S biosafety officer at (707)
826-5711 for a review of laboratory protocols and procedures.
Report adverse event incident to the IRB.

Procedure for Collection:
Blood
• Outside tips of ring or middle fingers will only be used as sample sites. Clean and
sterilize the area with an alcohol prep pad and allow moisture to evaporate before
testing or dry with sterile cotton square.
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• Using single-use safety lancet, hold cotton pad in one hand underneath the site and

apply pressure with lancet on ideal site. Prick finger of test subject and allow a
drop of blood to form on the surface of the skin. The first drop of blood may
contain perspiration and other contaminants so wipe clean with cotton square and
obtain a second drop of blood. Give the cotton square to the subject in the nonsampled hand so they can clot the sampling site after the sample has been
collected. Avoid squeezing the sampled finger because it introduces
contamination.
• The subject will place finger over the top of the blood collection tube and allow the
blood to fill the tube until 300µL is collected (about 2-4 drops).
• A band-aid will be applied after sample collection.
• Used cotton squares with blood can be disposed of in a regular trash bin per OSHA
standards.

Clean Up:
• Using a 70% isopropyl alcohol wipe, wipe down all equipment
• Properly dispose of lancets and contaminated collection supplies in designated
biohazard container after each use.
Procedures adapted from: Australian Sports Commission, Physiological Tests for Elite
Athletes (2000), ch 6.
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Appendix E: Whole Blood Homogenization Protocol
Step
1

Procedure
Prepare Homogenization Buffer w/ Protease (HB w/P) per manufacturer’s
instructions

2

Prep micro-centrifuge tubes with appropriate recoded ID numbers

2

Thaw blood samples on ice (keep on ice until plated)

3

Estimate and record total sample volume by comparing it against pre-measured,
water-filled micro-centrifuge tubes set at 50 μl intervals

4

Add HB w/ P at 1:10 ratio

5

Vortex for 2 – 5 second pulses

6

Visually check viscosity
6a. If solution is too runny, add 5 µl HB w/ P as needed and recheck viscosity

7

Record total sample volume + HB w/ P

8

Refreeze or plate sample

9

Repeat with next sample
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Appendix F: Final Whole Blood Assay Protocol

Step

Procedure

1

Obtain blood samples and store in -80 ℃

2

Homogenize samples in 1:10 ratio to homogenization buffer within 2 weeks of
storage

3

Dilute samples 1:50 to Sample Diluent solution

4

Assay samples and obtain response

5

Calculate plate’s Standard Curve

6

Complete statistics for converting plate responses to BDNF concentration values

7

Average duplicate sample BDNF concentration values

Note: Final Protocol for Assaying Whole Blood BDNF samples
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Appendix G: R Script
library(dplyr)
library(tidyr)
library(mice)
library(Amelia)
library(readr)
library(janitor)
library(lubridate)
library(ggplot2)
library(car)
library(multcomp)
library(ez)
library(tidyverse)
library(readr)
bdnfdata <- read_csv ("Desktop/bdnfdata.csv")
View(bdnfdata)
# replace with your own path
path <- ("Desktop/bdnfdata.csv")
# import and clean
bdnf <- readr::read_csv("Desktop/bdnfdata.csv") %>%
janitor::clean_names()
#turn into factors
bdnf <- bdnf %>%
separate(id, into = c('id', 'nothing'), sep = 1) %>%
mutate(x12hoursago = factor(x12hoursago),
id = factor(id),
sex = factor(sex),
sessions = factor(session),
re = factor(re))
View(bdnf)
#impute data
bdnf.t <- bdnf %>%
mice(m = 10, maxit = 10, method = 'pmm', seed = 1619) %>%
mice::complete()
View(bdnf.t)
missmap(bdnf)
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missmap(bdnf.t)
glimpse(bdnf.t)
####------------------------#### Exploratory Graphs
####------------------------install.packages("extrafont")
library(extrafont)
font_import()
loadfonts(device="win")
#Register fonts for Windows bitmap output
fonts()
library(Hmisc)
library(ggplot2)
#avg, those who did exercise had a higher median of BDNF levels vs. those who didn't
exercise
ggplot(bdnf.t, aes(x12hoursago, avgbdnf)) +
geom_point(alpha = 0.6) +
stat_summary(fun.data = 'mean_cl_normal', geom = 'crossbar', width = .3, col= 'red') +
theme_bw() +
theme(text=element_text(family="Times New Roman", face="plain", size=12)) +
labs(x="Exercise Response",y="BDNF Concentration (pg/mL)")
bdnf.t %>%
filter(re %in% c("1", "2")) %>%
group_by(re) %>%
summarize(the_medians = median(as.numeric(re), na.rm = TRUE))
#diff version
ggplot(bdnf.t, aes(x=x12hoursago, y=avgbdnf,fill=x12hoursago)) +
geom_point(alpha = 0.6) +
stat_summary(fun.data = 'mean_cl_normal', geom = 'crossbar', width = .3, col= 'red') +
theme_bw() +
scale_fill_discrete(name="Exercise Response",
breaks=c("1", "2"),
labels=c("Within 12 hours", "More than 12 hours ago")) +
theme(text=element_text(family="Times New Roman", face="plain", size=12)) +
xlab("Exercise Response") + ylab("BDNF Concentration (pg/mL)")
#overall bell curve of samples - looks pretty normal
ggplot(bdnf.t, aes(avgbdnf)) +
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geom_density(fill = 'lightblue', alpha = 0.8) +
theme_bw() +
labs(x="Average BDNF Conncentration (pg/ml)",y="Count")
#same but just in histogram bell curve form
ggplot(bdnf.t, aes(avgbdnf)) +
geom_histogram(fill = 'lightblue', alpha = 0.8) +
theme_bw() +
labs(x="Average BDNF Conncentration (pg/ml)",y="Count") +
theme(text=element_text(family="Times New Roman", face="plain", size=12)) +
theme(panel.grid.major = element_blank(), panel.grid.minor = element_blank())
#dichotomize M and F and those who exercise vs. not exercise
ggplot(bdnf.t, aes(avgbdnf)) +
geom_histogram(fill = 'lightblue', alpha = 0.8) +
facet_wrap(sex ~ x12hoursago) +
theme_bw()
####--------------------------------#### HYPOTHESIS 1: COEFFICIENT OF VARIANCE: OVERALL SD/OVERALL
MEAN
#### CALCULATED IN EXCEL ALREADY
####--------------------------------####--------------------------------#### HYPOTHESIS 2: Mixed effect model (repeated measures)
####--------------------------------library(lme4)
#### This model utilized mean imputation - leaning towards nonsig side b/c xhoursago =
-1.489
model1 <- lmer(avgbdnf ~ x12hoursago + (1|id), data = bdnf.t)
summary(model1)
model1
model2 <-lmer(avgbdnf ~ 1 + (1|id), data = bdnf.t)
model2
anova(model2, model1)
tapply(bdnf.t$avgbdnf,bdnf.t$x12hoursago, mean)
tapply(bdnf.t$avgbdnf,bdnf.t$x12hoursago, sd)
tapply(bdnf.t$avgbdnf,bdnf.t$x12hoursago, median)
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#There was no significant difference between recent exercise activity within 12 hours and
BDNF levels (χ2(1)=2.28, p=0.13)
r2.corr.mer <- function(m) {
lmfit <- lm(model.response(model.frame(m)) ~ fitted(m))
summary(lmfit)$r.squared}
r2.corr.mer(model1)
r2.corr.mer(model2)
#BDNF lvls and intensity
bdnf.t <- bdnf.t %>%
mutate (intensity.factor = as.factor(intensity))
View(bdnf.t)
str(bdnf.t$intensity.factor)
model1.int <- lmer(avgbdnf ~ intensity.factor + (1|id), data = bdnf.t)
summary(model1.int)
plot(model1.int)
model2.int <-lmer(avgbdnf ~ 1 + (1|id), data = bdnf.t)
model2.int
anova(model2.int, model1.int)
r2.corr.mer(model1.int)
r2.corr.mer(model2.int)
#descriptive statistics
tapply(bdnf.t$avgbdnf,bdnf.t$intensity.factor, mean)
tapply(bdnf.t$avgbdnf,bdnf.t$intensity.factor, sd)
tapply(bdnf.t$avgbdnf,bdnf.t$intensity.factor, median)
tapply(bdnf.t$avgbdnf, list(bdnf.t$intensity.factor,bdnf.t$sessions),mean)
tapply(bdnf.t$avgbdnf, list(bdnf.t$intensity.factor,bdnf.t$sessions),sd)
tapply(bdnf.t$avgbdnf, list(bdnf.t$intensity.factor,bdnf.t$sessions),median)
####--------------------------------#### POST HOC - Mixed effect model (repeated measures) FOR INTENSITY & BDNF
LEVELS
####--------------------------------bdnf.t <- bdnf.t %>%
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group_by(sessions,intensity.factor) %>%
mutate(mean.avgbdnf = mean(avgbdnf))
View(bdnf.t)
bdnf.t$intensity.factor <- factor(bdnf.t$intensity.factor, levels=c("none", "low", "mod",
"high"), labels=c("None", "Low", "Mod", "High"))
ggplot(data=bdnf.t, aes(x=sessions, y=mean.avgbdnf, group = intensity.factor,color =
intensity.factor, shape = intensity.factor)) +
geom_line(size = .25) +
geom_point() +
labs(x="Session",y="BDNF Concentration (pg/ml)") +
scale_linetype_discrete("Intensity") +
scale_shape_discrete("Intensity") +
scale_colour_discrete("Intensity") +
theme(text=element_text(family="Times New Roman", face="plain", size=12)) +
theme(panel.grid.major = element_blank(), panel.grid.minor = element_blank())
#do not run#
#There was no significant difference between intensity types within 12 hours and BDNF
levels Chi square (3,1) = 5.22, p = 0.15)
#intensity <- ordered(c("none", "low", "mod", "high"))
#intensity.factor<- ordered(intensity.factor, levels = c("none", "low", "mod", "high"))
#intensity
#looks at imputed model and the dots are pretty scattered
plot(model1)
# They lie kinda heavily on the linear line
library(car)
qqp(resid(model1))
library(dotwhisker)
dwplot(model1)
#EXPLORATORY: non-imputed data show no decision for participant 2, 6 and 7
bdnf%>%
group_by(id) %>%
dplyr::summarize(mean = mean(avgbdnf), sd = sd(avgbdnf), upper = mean + sd, lower
= mean - sd) %>%
mutate(within = ifelse((mean + sd) <= upper & (mean - sd) >= lower,
'TRUE', 'FALSE') )
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###### TO-DO
bdnf.t$avgbdnf
####--------------------------------#### ADDITIONAL POST HOC ANALYSES
####--------------------------------# 1 - Time Series Analysis
#new plot w/ better legend and also CV next to each participant
bdnf.time <- bdnf.t %>%
separate(id, into = c('id', 'nothing'), sep = 1) %>%
mutate(time = case_when(session == 1 ~ ymd(20170403),
session == 2 ~ ymd(20170405),
session == 3 ~ ymd(20170407),
session == 4 ~ ymd(20170410),
session == 5 ~ ymd(20170412),
session == 6 ~ ymd(20170414),
session == 7 ~ ymd(20170417),
session == 8 ~ ymd(20170419),
session == 9 ~ ymd(20170421),
session == 10 ~ ymd(20170424),
session == 11 ~ ymd(20170426),
session == 12 ~ ymd(20170428)),
recent_exercise = case_when(x12hoursago == 1 ~ "yes",
x12hoursago == 2 ~ "no"),
time_factor = as.factor(session),
time_test = ts(time),
avg_bdnf = mean(avgbdnf),
upper = avg_bdnf + (avgbdnf * .15),
lower = avg_bdnf - (avgbdnf * .15),
intensity = as.factor(intensity),
sex = as.factor(sex),
avgbdnf = round(avgbdnf,2),
id = as.factor(id),
session.2 = session*2) %>%
mutate(id = as.factor(id),
Participant = case_when(id == 1 ~ "1 (0.16)",
id == 2 ~ "2 (0.27)",
id == 3 ~ "3 (0.19)",
id == 4 ~ "4 (0.18)",

83
id == 5 ~ "5 (0.16)",
id == 6 ~ "6 (0.22)",
id == 7 ~ "7 (0.29)",
id == 8 ~ "8 (0.13)",
id == 9 ~ "9 (0.13)"))
View(bdnf.time)
ggplot(bdnf.time, aes(x = session.2, y = avgbdnf)) + geom_line(aes(color = Participant))
#rename axis titles
dat <-ggplot(data=bdnf.time, aes(x=session.2, y=avgbdnf, shape = id)) +
geom_line(aes(color = Participant)) +
geom_point() +
labs(x="Day",y="Average BDNF Concentrations (pg/mL)") +
theme(panel.grid.major = element_blank(), panel.grid.minor = element_blank()) +
theme(text=element_text(family="Times New Roman", face="plain", size=12))
print(dat + scale_shape_manual(values = c(0, 16, 3, 4, 5, 6, 7, 17, 18)))
dat + scale_shape_manual(values = c(0, 16, 3, 4, 5, 6, 7, 8, 9)) +
geom_line(aes(color = Participant)) +
guides(shape = FALSE) # you can switch this to color = FALSE instead if you want
#
print(dat + scale_shape_manual(values = c(0, 16, 3, 4, 5, 6, 7, 17, 18)) +
geom_line(aes(color = Participant)))
#
ggplot(data=dat, aes(x=session.2, y=avgbdnf, shape = id)) +
geom_line(aes(color = Participant)) +
geom_point(shape=1) +
labs(x="Day",y="Average BDNF Concentrations (pg/mL)") +
theme(panel.grid.major = element_blank(), panel.grid.minor = element_blank()) +
theme(text=element_text(family="Times New Roman", face="plain", size=12)) +
print(dat + scale_shape_manual(values = c(1, 2, 3, 4, 5, 6, 7, 8, 9)))
dat <- ggplot(bdnf.time, aes(session, avgbdnf, shape = id, colour = id)) + geom_point()
print(dat + scale_shape_manual(values = c(0, 16, 3, 4, 5, 6, 7, 8, 9)))
#### Post Hoc # 2: does BMI and BDNF correlate? No.
cor.test(bdnf.time$bmi,bdnf.time$avgbdnf)
#need effect size
#notes: power analysis for a correlation?
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pwr::pwr.r.test(n = 2200, r = .06, sig.level = .05)
#### Post Hoc # 3: Sex and bdnf averages over time correlation? Nope.
t.test(avgbdnf~sex,bdnf.time)
library(lsr)
lsr::cohensD(bdnf.time$avgbdnf~bdnf.time$sex)
#power analysis for gender correlation (maybe could even be repeated measures amt in
bdnf exercise group)
pwr::pwr.t.test(n = 222, d= .27, sig.level = .05)
### Post Hoc # 4 : Menstrual Phases (3) and BDNF levels
#Is there a difference between the Avgbdnf for females against their different menstrul
time periods.
#Follicular = Day 1-13, Luteal = Day 14-28. Nope.
females <- bdnf.time %>% filter(sex == "F") %>%
mutate(menstrul_1 = case_when(menstrul < 13 ~ "Follucular",
menstrul >= 13 & menstrul < 22 ~ "Luteal 1st half",
menstrul >= 29 ~ "Luteal 2nd half"),
menstrul_1 = as.factor(menstrul_1))
aov_menst <- aov(avgbdnf~menstrul_1,females)
Anova(aov_menst, type = 3) #type 3 b/c ~ spss output typical in APA
lsr::etaSquared(Anova(aov_menst, type = 3))

Testers <- glht(aov_menst,linfct=mcp(menstrul_1 = "Tukey"))
summary(Testers)
tapply(females$avgbdnf,females$menstrul_1, mean)
tapply(females$avgbdnf,females$menstrul_1, sd)
library(lsr)
lsr::cohensD(females$avgbdnf~females$menstrul_1)
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Appendix H: Linear Mixed Model Analysis for Exercise Response
Linear Mixed-Effects Analysis of Exercise Response and BDNF Levels
Exercise Intensity – Fixed Effects
Estimate SE

(Intercept)

t

31.60

2.69

11.744

Recent Exercise -2.69

1.81

-1.49

SE = Standard Error

Participant - Random Effects
Response
SD
ID

7.4

Recent Exercise
No Exercise

8.9
9.5

No Exercise

-0.40

Note: Estimates of variance/covariance are reported as
Standard deviation (SD) with correlations. SD of model
with only random effects residual= 6.49, N=9.
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Appendix I: Linear Mixed Model Analysis for Exercise Intensity
Exercise Intensity – Fixed Effects
Estimate
SE

(Intercept)

t

28.37

2.84

9.97

Low

5.39

2.40

2.25

Mod
High

2.62
1.17

1.82
2.27

1.44
0.52

SE = Standard Error

Participant - Random Effects
Intensity
ID

SD
7.42

None

Low

None
Low

9.27
11.32

-0.23

Mod

9.91

-0.28

0.46

High

33.56

-0.27

0.29

Mod

0.34

Note: Estimates of variance/covariance are reported as standard deviation (SD)
with correlations. SD of model with only random effects residual= 6.49, N=9.
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Appendix J: Duplicate Sample Variability for all Participants
Participant 1
Session
ID
Run 1
Run 2
|Run 1-Run 2|
1
1
34.35
36.28
1.93
2
1
49.78
46.28
3.5
3
1
30.4
35.66
5.26
4
1
34.95
33.84
1.11
5
1
33.31
32.99
0.32
6
1
31.62
38.93
7.31
7
1
43.95
32.8
11.15
8
1
50
37.17
12.83
9
1
37.5
21.75
15.75
10
1
25.51
35.01
9.5
11
1
54.48
35.24
19.24
12
1
38.07
34.38
3.69
Note: Raw data for sample duplicate runs and the variability
between each sample. Participant 1’s overall duplicate sample
variability averaged 7.6 pg/ml.
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Participant 2
Session
ID
Run 1
Run 2
|Run 1-Run 2|
1
2
57.51
37.35
20.16
2
2
58.3
52.2
6.1
3
2
18.79
32.42
13.63
4
2
32.63
10.19
22.44
5
2
33.56
46.49
12.93
6
2
39.46
47.03
7.57
7
2
35.03
31.74
3.29
8
2
61.6
36.79
24.81
9
2
10
2
39.74
13.91
25.83
11
2
44.59
36.68
7.91
12
2
35.65
43.48
7.83
Note: Raw data for sample duplicate runs and the variability
between each sample. The participant had a missing value for
the ninth session due to the sample running out during the
troubleshooting phases. Participant 2’s overall duplicate
samples variability averaged 14.2 pg/ml.
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Participant 3
Session
ID
Run 1
Run 2
|Run 1-Run 2|
1
3
28.06
45.7
17.64
2
3
42.24
31.04
11.2
3
3
25.12
41.81
16.69
4
3
21.49
21.95
0.46
5
3
27.27
25.84
1.43
6
3
25.74
31.03
5.29
7
3
24.02
26.49
2.47
8
3
18.82
29.62
10.8
9
3
19.15
23.44
4.29
10
3
25.43
23.31
2.12
11
3
32.02
25.48
6.54
12
3
33.99
23.44
10.55
Note: Raw data for sample duplicate runs and the variability
between each sample. Participant 3’s overall duplicate samples
variability averaged 7.5 pg/ml.

90
Participant 4
Session
ID
Run 1
Run 2
|Run 1-Run 2|
1
4
19.2
25.46
6.26
2
4
15.2
35.45
20.25
3
4
22.84
29.38
6.54
4
4
18.17
20.27
2.1
5
4
18.94
18.79
0.15
6
4
11.52
14.59
3.07
7
4
20.27
23.04
2.77
8
4
37.88
18.96
18.92
9
4
26.67
14.99
11.68
10
4
23.4
19.42
3.98
11
4
25.5
19.79
5.71
12
4
29.05
18.31
10.74
Note: Raw data for sample duplicate runs and the variability
between each sample. Participant 4’s overall duplicate samples
variability averaged 7.7 pg/ml.
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Participant 5
Session
ID
Run 1
Run 2
|Run 1-Run 2|
1
5
14.87
23.61
8.74
2
5
13.05
14.07
1.02
3
5
9.91
12.36
2.45
4
5
13.89
17.28
3.39
5
5
12.84
17.29
4.45
6
5
11.6
19.09
7.49
7
5
12.56
16.63
4.07
8
5
13.64
19.13
5.49
9
5
8.05
13.66
5.61
10
5
12.64
11.78
0.86
11
5
16
16.03
0.03
12
5
15.4
13.94
1.46
Note: Raw data for sample duplicate runs and the variability
between each sample. Participant 5’s overall duplicate samples
variability averaged 3.8 pg/ml.
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Participant 6
Session
ID
Run 1
Run 2
|Run 1-Run 2|
1
6
36.94
23.04
13.9
2
6
39.91
28.71
11.2
3
6
28.27
31.41
3.14
4
6
26.85
31.14
4.29
5
6
36.56
33.53
3.03
6
6
7
6
17.58
20.75
3.17
8
6
21.61
31.08
9.47
9
6
37.56
21.38
16.18
10
6
27.34
29.84
2.5
11
6
35.87
27.62
8.25
12
6
25.19
20.26
4.93
Note: Raw data for sample duplicate runs and the variability
between each sample. The participant had a missing value for
the sixth session due to the sample running out during the
troubleshooting phases. Participant 6’s overall duplicate samples
variability averaged 7.3 pg/ml.
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Participant 7
Session
ID
Run 1
Run 2
|Run 1-Run 2|
1
7
29.64
45.42
15.78
2
7
81.72
31.3
50.42
3
7
42.18
54.72
12.54
4
7
30.49
39.98
9.49
5
7
30.11
24.07
6.04
6
7
34.83
24.24
10.59
7
7
24.08
29.65
5.57
8
7
39.84
29.31
10.53
9
7
27.74
32.72
4.98
10
7
20.89
71.83
50.94
11
7
23.93
15.24
8.69
12
7
Note: Raw data for sample duplicate runs and the variability
between each sample. The participant had a missing value for
the ninth session due to the sample running out during the
troubleshooting phases. Participant 7’s overall duplicate samples
variability averaged 16.9 pg/ml.
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Participant 8
Session
ID
Run 1
Run 2
|Run 1-Run 2|
1
8
41.13
42.39
1.26
2
8
33.27
20.79
12.48
3
8
34.87
28.21
6.66
4
8
37.33
29.41
7.92
5
8
24.11
42.89
18.78
6
8
34.14
41.36
7.22
7
8
32.13
31.19
0.94
8
8
37.76
28.32
9.44
9
8
35.67
38.5
2.83
10
8
48.9
27.93
20.97
11
8
30.79
24.61
6.18
12
8
32.87
30.72
2.15
Note: Raw data for sample duplicate runs and the variability
between each sample. Participant 8’s overall duplicate samples
variability averaged 8.1 pg/ml.
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Participant 9
Session
ID
Run 1
Run 2
|Run 1-Run 2|
1
9
44.23
27.29
16.94
2
9
28.71
27.25
1.46
3
9
34.31
24.58
9.73
4
9
25.22
32.18
6.96
5
9
37.27
22.67
14.6
6
9
24.87
18.51
6.36
7
9
27.87
37.23
9.36
8
9
31.71
37.56
5.85
9
9
26.63
30.45
3.82
10
9
32.31
23.87
8.44
11
9
32.79
32.27
0.52
12
9
41.47
30.53
10.94
Note: Raw data for sample duplicate runs and the variability
between each sample. Participant 9’s overall duplicate samples
variability averaged 7.9 pg/ml.

